Hanson Wade

R&D
8th Annual Antifibrotic Drug Development Summart
Partner Content

8th Annual Antifibrotic Drug Development Summit

The landmark FDA approval of the first MASH therapeutic, the orphan drug designation for systemic sclerosis trials, and the rapid advancement of IPF treatments through clinical phases have ignited

R&D
6th Inflammasome Therapeutics Summit banner
Partner Content

6th Inflammasome Therapeutics Summit

In the rapidly evolving field of inflammasome therapeutics, the need for innovative approaches to overcome the preclinical and clinical hurdles is more critical than ever.